Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04620798 · ClinicalTrials.gov registry record · NA
Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students
A NA study, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 1,076
- Enrollment target
NCT04620798 is a NA study that has completed, run by Indiana University. The registered enrollment target is 1,076 participants.
The verdict
NCT04620798, a NA study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,076 participants
- Enrollment target
Study Summary
The primary goal for this study is to assess whether receiving the results of an antibody test changes protective behavior to avoid SARS-CoV-2 infections (i.e., mask-wearing, physical distancing, limiting close contacts/avoiding crowds, hand-washing, avoiding contact with high-risk individuals). While studies have been published on the cross-sectional relationship between risk perception and other demographic characteristics and health behaviors that are protective for SARS-CoV-2 infection (see citations), there have been no studies showing the effect of receiving information about antibody positivity on protective behavior. Not only can results from this study be used to better model transmission, a better understanding of college student's risk perception around SARS-CoV-2 infections has implications for future vaccination strategies as well. There are concerns that a desire to return to "normal" life in combination with reduced perception of risk could have negative consequences for uptake of vaccination (Johns Hopkins Center for Health Security 2020 report, The Public's Role in COVID-19 Vaccination: Planning Recommendations Informed by Design Thinking and the Social, Behavioral, and Communication Sciences). The antibody test used in this study is named 'SARS-CoV-2 IgM/IgG rapid assay kit (Colloidal Gold)'. It provides a fast, on-site, and accurate detection of IgM/IgG antibodies against SARS-CoV-2, with positive results of IgM antibodies indicating a recent infection, while positive results of IgG antibodies signaling a longer or previous infection. It can detect IgM and IgG antibodies against SARS-CoV-2 in human specimens of serum, plasma, or venous whole blood.
Interventions
- BEHAVIORAL Immediate vs. delayed provision of antibody test results
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,076 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2020-11-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04620798
The ClinicalTrials.gov registry entry for NCT04620798 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,076 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Immediate vs. delayed provision of antibody test results is the first listed.
NCT04620798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04620798 about?
NCT04620798 is a clinical study titled "Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students". The primary goal for this study is to assess whether receiving the results of an antibody test changes protective behavior to avoid SARS-CoV-2 infections (i.e., mask-wearing, physical distancing, limiting close contacts/avoiding crowds, hand-washing, avoiding contact with high-risk individuals). Whi...
What is the current status of trial NCT04620798?
This trial is currently completed. It is a NA study. The enrollment target is 1,076 participants. The study started on 2020-09-14. Estimated completion is 2020-11-11.
What interventions are being tested in trial NCT04620798?
The interventions under investigation include: Immediate vs. delayed provision of antibody test results (BEHAVIORAL).
Who is sponsoring clinical trial NCT04620798?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.